Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 5,235 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Myositis
Interventions: Nipocalimab, Placebo, Glucocorticoids; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 19
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more

Conditions: Hypercholesterolemia
Interventions: Bempedoic acid 180mg, Ezetimibe 10mg, Atorvastatin 20mg, Placebo; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 11
States / cities: Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 7 more

Conditions: Demodex Blepharitis
Interventions: GLK-321 low dose BID, GLK-321 mid dose BID, GLK-321 high dose BID, GLK-321 high dose QD, Placebo BID; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: HIV Preexposure Prophylaxis
Interventions: ISL, FTC/TDF, FTC/TAF, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more

Conditions: Multiple Sclerosis
Interventions: Placebo, Teriflunomide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • Loma Linda, California + 35 more

Conditions: Nausea and Vomiting, Postoperative
Interventions: Ondansetron, Placebo; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Hip Surgery Corrective, Anesthesia; Functional
Interventions: Drug group Fascia iliaca nerve block, Control group sham nerve block; Procedure
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sedentary Behavior, Lack of Physical Activity, Physical Inactivity
Interventions: LADIES online intervention (R33 phase), LADIES online control (R33 phase); Behavioral
Lead sponsor: Gramercy Research Group; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Knightdale, North Carolina

Conditions: Amphetamine-Related Disorders
Interventions: Reserpine; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Actinic Keratosis
Interventions: Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 17
States / cities: Fremont, California • Los Angeles, California • San Diego, California + 14 more

Conditions: Acute Ischemic Stroke
Interventions: DP-b99, Placebo; Drug
Lead sponsor: D-Pharm Ltd.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 13
States / cities: Oceanside, California • Danbury, Connecticut • Savannah, Georgia + 10 more

Conditions: Neurogenic Urinary Bladder
Interventions: Alfuzosin, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: Bifeprunox; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Orange, California

Conditions: Alcohol Dependence, Alcohol Use Disorder
Interventions: XR-NTX+CM (Extended-Release Naltrexone plus Care Management); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Menopause
Interventions: Ashoka Bark and Shatavari, Placebo; Dietary Supplement · Other
Lead sponsor: Vidya USA Corporation; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Port Richey, Florida

Conditions: Restless Legs Syndrome (RLS), Restless Legs Syndrome
Interventions: Ropinirole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 49
States / cities: Alabaster, Alabama • Birmingham, Alabama • Jasper, Alabama + 44 more

Conditions: Type 2 Diabetes
Interventions: AZD1656; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Alopecia Areata
Interventions: Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Encinitas, California • Miami, Florida • Skokie, Illinois + 13 more

Conditions: Cholera
Interventions: PXVX0200, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 46 Years to 64 Years
Enrollment: 398 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 16
States / cities: Mobile, Alabama • DeLand, Florida • Miami, Florida + 12 more

Conditions: Osteoarthritis
Interventions: PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid; Drug · Other
Lead sponsor: POZEN; Industry
Eligibility: 50 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acromegaly
Interventions: ALXN2420, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Torrance, California • Ann Arbor, Michigan

Conditions: Erectile Dysfunction
Interventions: Shockwave Therapy, SHAM shockwave therapy; Device · Other
Lead sponsor: University of Miami; Other
Eligibility: 40 Years to 75 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Painful Diabetic Neuropathy, Diabetic Neuropathy, Neuropathy
Interventions: Clonidine Gel 0.1%, Placebo; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 23
States / cities: Phoenix, Arizona • Santa Monica, California • Walnut Creek, California + 20 more

Conditions: Common Cold, Infections, Upper Respiratory Tract
Interventions: Dextromethorphan, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Pinellas Park, Florida • Indianapolis, Indiana • Gresham, Oregon + 1 more

Search by objective public record fields.

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis

Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy

Effectiveness of Fascia Iliaca Nerve Block for Post Hip Arthroscopy

Feasibility and Acceptability of an Online Program to Promote Physical Activity Among Black Women

A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

Satavari and Ashoka for Menopause (SAM) Study

A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome

A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

Clinical Trial of Low Intensity Shockwaves Therapy for Erectile Dysfunction Post-Radical Prostatectomy

Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy

Acute Cough Study In Children